ERS Genomics and Lonza Enter Into CRISPR/Cas9 Technology Licensing Deal

ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics CRISPR/Cas9 genome editing technology patents. Lonza will have the ability to utilize CRISPR/Cas9 in its bioproduction products and services and also for use in induced pluripotent stem cells (iPSC) for research applications.

Lonza is the worlds leading contract manufacturing organization of biologics and we are thrilled that they have chosen to use CRISPR/Cas9 to enhance their capabilities, commented Eric Rhodes, CEO of ERS Genomics. We see tremendous potential for the use of gene editing to enhance the manufacturing of biologics and I expect Lonza will certainly be leading the way.

Financial details of the agreement were not disclosed.

ERS Genomics was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology:


Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Mario Brkulj or Kara Mazey
MacDougall Biomedical Communications
[email protected]
+49 89 2420 9345 or +1 781 235 3060